| Literature DB >> 35991891 |
Shihao Zheng1, Tianyu Xue1, Bin Wang1, Haolin Guo1, Qiquan Liu1,2.
Abstract
Network pharmacology was rapidly developed based on multidisciplinary holistic analysis of biological systems, which has become a popular tool in traditional Chinese medicine (TCM) research in recent years. Its characteristics of integrity and systematization provide a new approach for the study on complex TCM systems, which has many similarities with the holistic concept of TCM. It has been widely used to explain the mechanism of TCM treatment of diseases, drug repositioning, and interpretation of compatibility of TCM prescriptions, to promote the modernization of TCM. The use of TCM have provided crucial support on prevention and treatment of diseases such as the famous "three medicines and three prescriptions". Furthermore, TCM has become an important part of the treatment of COVID-19 and is one of the main contents of the "Chinese plan" to fight the epidemic. The current review demonstrated the role of TCM in treating diseases with multiple components, multiple targets, and multiple pathways, interprets the connotation of TCM treatment method selection based on pathogenesis and also discusses the application of network pharmacology in the study of COVID-19 treatment in TCM including single drug and prescription. However, there are still some shortcomings such as the lack of experimental verification and regular upgrading of the TCM pharmacology network. Therefore, we must pay attention to the characteristics of TCM and develop a network pharmacology method suitable for TCM system research when applying network pharmacology to TCM research.Entities:
Keywords: COVID-19; mechanism of action; network pharmacology; review; traditional Chinese medicine pharmacology
Year: 2022 PMID: 35991891 PMCID: PMC9387999 DOI: 10.3389/fphar.2022.926901
Source DB: PubMed Journal: Front Pharmacol ISSN: 1663-9812 Impact factor: 5.988
Network pharmacology analysis of TCM in the treatment of COVID-19.
| References | Formulae & Herbs | Objects | Main ingredients | Main targets | Main signaling pathways | Outcome |
|---|---|---|---|---|---|---|
| Wang et al. (2021a) | R. Crenulata | Molecular Docking | Quercetin, Kaempferol, Tamarixetin | IL6, IL1B, TNF | TNF, IL-17 | R. crenulata can play an immunoregulatory and anti-inflammatory role in the cytokine storm of COVID-19 |
| Yu et al. (2021) | Banlangen | None | Acacetin, Isovitexin, Isaindigodione | PTGS1, PTGS2, PPARG | TNF, IL-17, RAGE | Banlangen has a potential pharmacological effect on the treatment of COVID-19 |
| Mu et al. (2021) | Rhizoma Polygonati | Molecular Docking | Diosgenin, Beta-sitosterol, Sitosterol | CASP3, TP53, PTGS2 | MAPK, Hepatitis B, Pathways in cancer | Potential compounds in Rhizoma Polygonati can act on different targets with cancer and viral related signaling and have a potential in treatment of COVID-19 |
| Qin et al. (2021) | Pueraria root | Molecular Docking | Puerarin | TNF, CASP3, CASP8 | IL-17, MAPK, Apoptosis | Related target genes of puerarin can regulate lung inflammation and oxidative stress response |
| Banerjee et al. (2021) | AP | None | Andrographolide | FABP5, FGF1, GLI1 | MAPK, Toll-like receptor, PI3K/AKT | Andrographolide can reduce the production of pro-inflammatory factors and cytokines in viral infection |
| Xiao et al. (2021) | Resverarum | Molecular Docking | Resveratrol | MMP9, MMP13, KCNH2 | TNF, NF-κB, IL-17 | Resveratrol can further alleviate the hyperinflammatory response of COVID-19 |
| Liu et al. (2021) | Sophora flavescens Ait | Male C57BL/6 mice | Matrine | TP53, AKT1, IL6 | C-type lectin receptor, PI3K-Akt, Toll-like receptor | Matrine may achieve simultaneous intervention of COVID-19 combined with liver injury by multi-dimensional pharmacological mechanism |
| Gao et al. (2020) | Ephedra-bitter almond | Molecular Docking | β-sitosterol, Stigmasterol, Estrone | PTGS2, HSP90AA1, AR | IL-17, TNF, PI3K-Akt | Ephedra-bitter can treat and prevent COVID-19 by inhibiting virus reproduction, regulating immune response and promoting body repair |
| Li et al. (2021b) | Ephedra-Glycyrrhiza pair | Molecular Docking | DehydroglyaspErins C, Phaseol, Gancaonin H | FOS, PTGS2, IL2 | PI3K-Akt, JAK-STAT | Ephedra-Glycyrrhiza pair can control PI3K-Akt signaling pathway to exert organ protection, antiviral and immune regulation effects |
| Lin et al. (2021) | Yinqiao powder | Molecular Docking, SPR assay | Quercetin, Naringin, Luteolin | TP53, MAPK3, IL-6 | MAPK, TNF, Toll-like receptor, T-cell receptor | Its antagonistic action against COVID-19 is mainly related to the regulation of inflammation-related proteins |
| Li et al. (2021a) | SHXP | Molecular Docking | Quercetin, Kaempferol, Luteolin | IL6, IL10, EGFR | HIF-1, NF-κB, Toll-like receptor | SHXP is a treatment for severe COVID-19 by regulating the cytokine storm of the human immune system and inhibiting viral growth |
| Tao et al. (2020) | HSBDF | Molecular Docking | Baicalin, Quercetin | MAPK3, MAPK8, TP53 | TNF, MAPK, PI3K-Akt, Nod-like receptor | Quercetin and baicalein in HSBDF can regulate multiple signaling pathways through ACE2, which may play a therapeutic role on COVID-19 |
| Li et al. (2021c) | MXSGD | IL-6 induced rat lung epithelial type II cells | Amygdalin, Spinacen, Euchrenone | STAT3, BAX, CASP3 | JAK-STAT | The key target of MXSGD can effectively inhibit the damage of RLE-6TN cells and exert its therapeutic effects through the JAK-STAT signaling pathway |
| Wang et al. (2021b) | MXYGD | Molecular Docking | Quercetin, Luteolin, Formononetin | IL4, IL6, CASP3 | PI3K-Akt, Chemokine, HIF-1 | MXYGD plays an significant role in the prevention and treatment of COVID-19 by activating lymphocytes, T cells,leukocytes, and other immune and anti-inflammatory effects |
| Xia et al. (2020) | LQC | Molecular Docking, AKT1 encoding protein | Beta-carotene, Kaempferol, Luteolin | AKT1, JUN, MAPK8 | Toll-like receptor, IL-17, TNF | LQC may provide a potentially effective treatment for COVID-19, reducing lung tissue damage and effectively relieving symptoms |
| Zheng et al. (2020a) | LHQW | None | Kaemperol, Luteolin, Catechin | PIK3CG, TLR3, PRKCB | JAK-STAT, Pathways in cancer | LHQW modulates the inflammatory process, repairs lung injury and exerts antiviral effects |
| Kong et al. (2020) | PDL | Molecular Docking | Oxysophocarpine, Isoacolamone, Adenosine | EGFR, TNF, IL-6 | Toll-like receptor, MAPK | PDL may have therapeutic effects on COVID-19 through three aspects, including the anti-virus entry into cells,moderate immune system, and anti-inflammation |
| Yan et al. (2020) | Qingfei Paidu Decoction | Molecular Docking | Coniferin, Gallic, Delphinidin | AGTR1, TNF, CASP3 | Apoptosis, RAS | Qingfei Paidu decoction might treat COVID-19 through its multiple medicinal ingredients that have various targets and signaling pathways |
| Ye et al. (2021b) | SQW | Molecular Docking | Luteolin, Quercetin, Kaempferol | ACE2, IL6, NOS3 | HIF-1, TNF, IL-17 | SQW can have anti-COVID-19 effects through the immune-inflammatory pathway |
| Zheng et al. (2020b) | XBJ | Molecular Docking | 5-hydroxymethyl-furfural, Albiflorin, Apigenin | ALB, EGFR, TNF | HIF-1, TNF, PI3K-Akt, NF-κB | XBJ can regulate different genes, act on different pathways, and synergize immunoregulatory and anti-inflammatory effects in COVID-19 |
| Xing et al. (2020) | XBJ | Molecular Docking | Luteolin, Apigenin, Quercetin | IL6, MAPK1, TNF | Toll-like receptor, TNF, T cell receptor, Prolactin | XBJ could play the role of anti-inflammatory, immune responseand anti-virus to treat COVID-19 |
| Ye et al. (2021a) | TGQ | Molecular Docking, SPR experiment | Ritonavir, Ribavirin, Lopinavir | IL6, PTGS2, TNF | IL17, TNF | TQG might have a therapeutic effect on COVID-19 by regulating immune, inflammation and viral infection related targets and pathways |
| Han et al. (2020) | CDPF | Molecular Docking | Quercetin, Luteolin, l-tyrosine | IL6, TNF, IL10 | TNF, Oxytocin, MAPK | CDPF mainly plays antiviral, immunomodulatory and anti-inflammatory effects in the treatment of COVID-19 |
| Xu et al. (2021) | Chansu injection | Molecular Docking | Bufalin, Resibufogenin, Cinobufagin | AKT2, GRB2, EGFR | JAK-STAT, PI3K-Akt, MAPK, FoxO | Chansu injection could regulate activate immune cells, virus duplication, and alleviate inflammatory responses through the JAK-STAT and PI3K-Akt signaling pathways |
| Zhang et al. (2020c) | RDS | Molecular Docking, Phytochemical analysis of RDS | Luteolin, Quercetin, Fisetin | NCOA1, RXRA, NCOA2 | Prolactin, IL17, HIF-1 | RDS has certain preventive and therapeutic effects on early COVID-19 |
Key signaling pathways in the treatment of COVID-19.
| No. | Name | Entry | Class | Disease | References |
|---|---|---|---|---|---|
| 1 | Pathways in cancer | map05200 | Human diseases, Cancer: overview | COVID-19 | Mu et al. (2021) |
|
| |||||
| 2 | NF-κB | map04064 | Environmental information processing Signal transduction | COVID-19 | Xiao et al. (2021) |
|
| |||||
|
| |||||
| 3 | IL17 | map04657 | Organismal systems, Immune system | COVID-19 | Wang et al. (2021a) |
|
| |||||
|
| |||||
| 4 | MAPK | map04010 | Environmental information processing, Signal transduction | COVID-19 | Banerjee et al. (2021) |
|
| |||||
|
| |||||
| 5 | PI3K-Akt | map04151 | Environmental information processing, Signal transduction | COVID-19 | Li et al. (2021b) |
|
| |||||
|
| |||||
| 6 | TNF | map04668 | Environmental information processing, Signal transduction | COVID-19 | Ye et al. (2021a) |
|
| |||||
|
| |||||
| 7 | JAK/STAT | map04630 | Environmental information processing, Signal transduction | COVID-19 | Li et al. (2021b) |
|
| |||||
|
| |||||
| 8 | HIF-1 | map04066 | Environmental information processing, Signal transduction | COVID-19 | Wang et al. (2021b) |
|
| |||||
|
| |||||
| 9 | Toll-like receptor | map04620 | Organismal systems, Immune system | COVID-19 | Liu et al. (2021) |
|
| |||||
|
| |||||
| 10 | Apoptosis | map04210 | Cellular processes, Cell growth and death | COVID-19 | Qin et al. (2021) |
|
|